Analysts expect Eton Pharmaceuticals to report an earnings per share (EPS) of $0.03. The announcement from Eton ...

A total of 5 analyst ratings have been received for Zevra Therapeutics, with the consensus rating being Buy. The average one-year price target stands at $22.0, suggesting a potential 179.54% upside.

One of the cannabis companies trying mightily to succeed is Tilray Brands (NASDAQ: TLRY), which shed more than 26% of its ...

Tilray Brands (NasdaqGS:TLRY) launched a new beverage line, "Cruisies," focusing on ready-to-drink cocktails. This product-related announcement coincided with a period when Tilray's shares rose 10%, ...

Tilray Inc (NASDAQ:TLRY – Free Report) – Alliance Global Partners reduced their FY2025 earnings estimates for shares of Tilray in a research report issued to clients and investors on Wednesday ...

The company posted declines in key fundamentals in its latest earnings report and cut revenue ... Those challenges are a constant drag. Meanwhile, Tilray has been attempting to cope with ...

Tilray Brands missed Q3 expectations but improved its balance sheet, with net debt at $14 million. Read why I maintain my ...

The firm has a market capitalization of $421.94 million, a price-to-earnings ratio of -1.50 and a beta of 1.88. Tilray (NASDAQ:TLRY – Get Free Report) last issued its quarterly earnings results ...

The stock market has been crashing this year and if you're a long-term investor, it can be a good time to invest in companies at discounted valuations. But that doesn't mean that you should be ...

In other recent news, Tilray Inc. reported its third-quarter 2025 financial results, revealing a significant revenue miss and a larger-than-expected net loss. The company’s earnings per share ...

Adjusted earnings are expected to come in at $1.61 ... beating analysts’ expectations by 1.9%, and Tilray reported a revenue decline of 1.4%, falling short of estimates by 10.1%.

Adjusted earnings are expected to come in at $1.61 per share ... beating analysts’ expectations by 1.9%, and Tilray reported a revenue decline of 1.4%, falling short of estimates by 10.1%.